Cancer Clinical Trials in Shenzhen, Guangdong
33 recruitingShenzhen, Guangdong, China
Showing 1–20 of 33 trials
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled262 locationsNCT07063745
Recruiting
Phase 1Phase 2
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Primary Peritoneal CarcinomaFallopian Tube CarcinomaEpithelial Ovarian Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07480954
Recruiting
Phase 1Phase 2
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
SCLC,Extensive StageSmall Cell Lung Cancer ( SCLC )Relapsed/Refractory SCLC
Beijing Biotech60 enrolled1 locationNCT07480213
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Non-small Cell Lung CancerAdvanced/Metastatic NSCLC
Beijing Biotech48 enrolled1 locationNCT07467863
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
Colorectal Cancer MetastaticAdenocarcinoma of Colon
Beijing Biotech48 enrolled1 locationNCT07462650
Recruiting
Phase 2
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positvie ctDNA After lead-in Osimertinib Monotherapy
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials120 enrolled4 locationsNCT07375316
Recruiting
Phase 3
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.416 enrolled69 locationsNCT07047365
Recruiting
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
Non-small Cell Lung CancerReal World StudyObservational Study+3 more
Peking University Shenzhen Hospital20 enrolled1 locationNCT07374614
Recruiting
Early Phase 1
Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer
Metastatic Colorectal CancerCRC (Colorectal Cancer)
Wondercel Biotech (ShenZhen)30 enrolled2 locationsNCT06653010
Recruiting
Not Applicable
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
Non-small Cell Lung Cancer
Sun Yat-sen University1,124 enrolled23 locationsNCT06524427
Recruiting
Not Applicable
RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
Locally Advanced Non-Small Cell Lung Cancer
Capital Medical University911 enrolled1 locationNCT07164885
Recruiting
Phase 2
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.270 enrolled25 locationsNCT06496490
Recruiting
Phase 2Phase 3
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled30 locationsNCT06891833
Recruiting
Phase 1Phase 2
Intervention of Bladder Cancer by CAR-T
Bladder CancerUrothelial Carcinoma Bladder
Shenzhen Geno-Immune Medical Institute20 enrolled2 locationsNCT03185468
Recruiting
Phase 1Phase 2
Genetically Modified T Cells Against Ovarian Cancer
Ovarian Cancer
Shenzhen Geno-Immune Medical Institute100 enrolled1 locationNCT03184753
Recruiting
A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
Ovarian Cancer RecurrentEndometrial Cancer RecurrentCervical Cancer Recurrent
Sun Yat-sen University200 enrolled2 locationsNCT06781151
Recruiting
Phase 1Phase 2
Prostate Cancer Vaccines
Prostate Cancer Indications
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT07068555
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
Pancreatic Cancer Metastatic
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center23 enrolled1 locationNCT07040228
Recruiting
Early Phase 1
Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer
Metastatic Colorectal CancerCRC (Colorectal Cancer)
Wondercel Biotech (ShenZhen)30 enrolled2 locationsNCT06675513